Leqembi approved for the treatment of Alzheimer’s disease in Israel
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic name: lecanemab) has been approved for treatment of Alzheimer’s disease (AD) in Israel. Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Israel is the sixth territory to approve Leqembi following the US, Japan, China, South Korea and Hong Kong.Leqembi’s approval in Israel is based on the large global Phase 3